Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

about

A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against Clostridium difficile.

P2860

Q55333418-E151EA6D-0679-41D5-9F1D-F0B437B485A3

P2860

Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

Item

http://www.wikidata.org/entity/Q54245367

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

@en

Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

@nl

type

Item

label

Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

@en

Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

@nl

prefLabel

Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

@en

Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

@nl

P1476

Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection

@en

P2093

Karl H Weiss

http://www.w3.org/2001/XMLSchema#string

Niels Steinebrunner

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon.

Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review

Clostridium difficile infection: new developments in epidemiology and pathogenesis

Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.

Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.

Burden of Clostridium difficile infection in the United States.

Clostridium difficile--more difficult than ever.

A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.

Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.

Breakthroughs in the treatment and prevention of Clostridium difficile infection.

P304

118-120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.21037/JTD.2017.12.117

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

W Stremmel

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29600036

http://www.w3.org/2001/XMLSchema#string

P921

Clostridium difficile

P932

5863157

http://www.w3.org/2001/XMLSchema#string

Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

about

P2860

P2860

Ridinilazole-a novel antibiotic for treatment of Clostridium difficile infection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932